Publications
51
Citations
582
Est. group size
~2
Recurring co-author estimate
Active years
11
Publishing since 2016
Zeinab El Boghdadly's research focuses on infectious complications in patients with blood cancers and those undergoing advanced cellular therapies like CAR-T cell treatment and stem cell transplantation. Work includes studying bloodstream infections, antibiotic management strategies, and COVID-19 vaccination guidance for immunocompromised cancer patients. Much of this research draws on large real-world patient databases to understand infection risks tied to newer cancer treatments.
Publication output has fluctuated over the past decade, rising from a low base around 2017 to a peak in 2020, dipping in 2023, and then increasing again through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Comparing infectious risk of Trastuzumab-deruxtecan to Trastuzumab-emtansine in patients with breast cancer
Breast Cancer Research and Treatment · 2026
- Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR
Blood Advances · 2025
- Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis
Blood Advances · 2025
- P-1671. Variation in clinical practice and attitudes on antimicrobial prophylaxis for patients undergoing chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies: a survey of cancer centers across the United States
Open Forum Infectious Diseases · 2025
- Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies
Transplant Infectious Disease · 2024
- Respiratory Viral Infections
2023
- Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology
UNC Libraries · 2023
- Bloodstream Infections in Hematologic Malignancy Patients With Fever and Neutropenia: Are Empirical Antibiotic Therapies in the United States Still Effective?
Open Forum Infectious Diseases · 2022
- Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
Transplantation and Cellular Therapy · 2022
- Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology
Transplantation and Cellular Therapy · 2022
- Transplant Providers’ Perceptions of COVID-19 Vaccination in the Wake of a Global Pandemic
Transplantation and Cellular Therapy · 2022
- Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients
Supportive Care in Cancer · 2021
- Infectious Challenges with Novel Antibody–Based Therapies
Current Infectious Disease Reports · 2021
- Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
Biology of Blood and Marrow Transplantation · 2020
- Clinical Impact of an Antibiotic Time Out Initiative at an Academic Medical Center
Hospital Pharmacy · 2020
- Open Forum Infectious Diseases×10
- Transplantation and Cellular Therapy×7
- Blood×6
- Biology of Blood and Marrow Transplantation×5
- Blood Advances×2
- Chunyu Xu
Medicine · Purdue University West Lafayette
- Jay K. Mandula
Medicine · The Ohio State University
- April Rahrig
Medicine · Indiana University
- Bihui Cao
Medicine · Indiana University
- John V. Napoleon
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile